Literature DB >> 8572901

Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.

H Kuśnierczyk1, W M Chołody, J Paradziej-Lukowicz, C Radzikowski, J Konopa.   

Abstract

Toxicity and antitumor effects of four compounds from the groups of triazoloacridinones and imidazoacridinones were evaluated in transplantable tumor systems in mice, including P388 leukemia, B16 melanoma and 2 colon adenocarcinomas C26 and C38. Tested compounds had moderate antileukemic activity but were active against B16 melanoma and 3 of them were very efficacious against colon tumors, providing high percentages of "cures". Toxicity for healthy mice, as well as antitumor activity, were found to depend on a treatment protocol. The compounds were better tolerated and gave higher antitumor effects when given as fractionated treatment. They displayed also sex-dependent toxicity and activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8572901

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  12 in total

1.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

2.  CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells.

Authors:  Ewa Augustin; Barbara Borowa-Mazgaj; Agnieszka Kikulska; Milena Kordalewska; Monika Pawłowska
Journal:  Acta Pharmacol Sin       Date:  2012-11-19       Impact factor: 6.150

3.  Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Authors:  Monika Pawlowska; Rong Chu; Barbara Fedejko-Kap; Ewa Augustin; Zofia Mazerska; Anna Radominska-Pandya; Timothy C Chambers
Journal:  Drug Metab Dispos       Date:  2012-11-16       Impact factor: 3.922

4.  Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Authors:  Barbara Fedejko-Kap; Stacie M Bratton; Moshe Finel; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2012-06-01       Impact factor: 3.922

5.  Combined anticancer therapy with imidazoacridinone analogue C-1305 and paclitaxel in human lung and colon cancer xenografts-Modulation of tumour angiogenesis.

Authors:  Marta Świtalska; Beata Filip-Psurska; Magdalena Milczarek; Mateusz Psurski; Adrianna Moszyńska; Aleksandra M Dąbrowska; Małgorzata Gawrońska; Karol Krzymiński; Maciej Bagiński; Rafał Bartoszewski; Joanna Wietrzyk
Journal:  J Cell Mol Med       Date:  2022-06-14       Impact factor: 5.295

6.  Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation.

Authors:  J Lamb; D N Wheatley
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

7.  Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers.

Authors:  Y Adar; M Stark; E E Bram; P Nowak-Sliwinska; H van den Bergh; G Szewczyk; T Sarna; A Skladanowski; A W Griffioen; Y G Assaraf
Journal:  Cell Death Dis       Date:  2012-04-05       Impact factor: 8.469

8.  Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities.

Authors:  Krzysztof Lemke; Marcin Wojciechowski; William Laine; Christian Bailly; Pierre Colson; Maciej Baginski; Annette K Larsen; Andrzej Skladanowski
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

9.  Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.

Authors:  A M Burger; J A Double; J Konopa; M C Bibby
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311.

Authors:  A M Burger; T C Jenkins; J A Double; M C Bibby
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.